An analysis of factors influencing short-term and sustained response to infliximab treatment for XXXX .

@entity1 @entity30 @entity1049
BACKGROUND: 59-81% of @entity1 given infliximab for @entity30 will respond. Although now in widespread use, little consensus exists regarding the optimal place in @entity1 care. Recently developed guidelines have identified need for markers that predict response. AIMS: We aimed to identify markers of response to infliximab given for @entity30 . METHODS: Markers of response (defined at 4 weeks) were prospectively assessed in 74 infliximab-treated @entity1 with @entity30 . @entity1 were followed-up to 1 year. RESULTS: Fifty-four of 74 (73%) @entity1 responded. Univariate analysis identified that smokers were less likely to respond than non-smokers [P = 0.005, odds ratio (OR) 0.22]. @entity1 established on immunosuppression (P = 0.034, OR 7.31) and with isolated @entity1049 (P = 0.042, OR 3.83) were more likely to respond. Multiple logistic regression confirmed smoking (P = 0.035, OR 0.24) and @entity1049 (P = 0.035, OR 4.87) as independent markers of response. One-year relapse rates differed significantly between smokers and non-smokers (100% vs. 39.6%, P = 0.0026, relative risk 3.2) and between @entity1 established on immunomodulators or not (58.0% vs. 92.8%, P = 0.0054, relative risk 2.6). CONCLUSIONS: Smoking has a strong adverse effect on the response rates and maintenance of response to infliximab. @entity1 on immunomodulators have a more favourable short- and long-term response. These results have important implications for clinical practice.
